Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Margaux Boehler"'
Autor:
Cristina Riccadonna, Céline Yacoub Maroun, Romain Vuillefroy de Silly, Margaux Boehler, Marta Calvo Tardón, Simone Jueliger, Pietro Taverna, Leticia Barba, Eliana Marinari, Serena Pellegatta, Esen Yonca Bassoy, Denis Martinvalet, Pierre-Yves Dietrich, Paul R Walker
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0162105 (2016)
Malignant gliomas are aggressive brain tumours with very poor prognosis. The majority of glioma cells are differentiated (glioma-differentiated cells: GDCs), whereas the smaller population (glioma-initiating cells, GICs) is undifferentiated and resis
Externí odkaz:
https://doaj.org/article/72e60fa9bc9e436c83a4f1a186e53b28
Publikováno v:
The Journal of Clinical Pharmacology. 59:123-130
ACT-246475 is a selective and reversible P2Y12 receptor antagonist inducing inhibition of platelet aggregation (IPA). A randomized, double-blind, placebo-controlled, parallel-design study was performed to investigate the safety, tolerability, pharmac
Publikováno v:
European Journal of Clinical Pharmacology. 73:1121-1128
In vitro data showed that selexipag and its active metabolite (ACT-333679) have an inductive effect on CYP3A4, CYP2B6, and CYP2C9 at concentrations approximately 100-fold higher than the maximum plasma concentration (C max) measured under steady-stat
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 43:115-120
Selexipag is an oral, non-prostanoid, selective prostacyclin receptor agonist recently marketed for the treatment of pulmonary arterial hypertension (PAH) in adults. Selexipag may also be an effective treatment in children with PAH. The aim of this s
Autor:
Joop M. A. van Gerven, Sander Brooks, Margaux Boehler, Jasper Dingemanse, Rob Zuiker, Clemens Muehlan
Publikováno v:
Journal of Psychopharmacology, 34(3), 326-335. SAGE PUBLICATIONS LTD
Background: The dual orexin receptor antagonist ACT-541468 showed sedative pharmacodynamic effects during initial clinical testing in adult subjects. The present study explored pharmacokinetics, pharmacodynamics and tolerability in healthy elderly su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8268d69417432eaaad1bb072888efbdb
https://hdl.handle.net/1887/3181508
https://hdl.handle.net/1887/3181508
Absolute Bioavailability of Ponesimod, a Selective S1P1 Receptor Modulator, in Healthy Male Subjects
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 42:129-134
The pharmacokinetic profile of ponesimod, a sphingosine-1-phosphate receptor 1 modulator, is characterized by a rapid absorption [time to maximum concentration (t max) of 2–4 h] and a terminal half-life (t ½) of 32 h after single-dose administrati
Publikováno v:
Journal of clinical pharmacology. 59(1)
ACT-246475 is a selective and reversible P2Y
Autor:
Jasper Dingemanse, Tatiana Remeňová, Margaux Boehler, Atef Halabi, Shirin Bruderer, Marc Petersen-Sylla
Publikováno v:
British journal of clinical pharmacology. 83(12)
Aims Based on in vitro data, there is evidence to suggest that cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT-333679. The present study evaluated the possible pharmacokinetic interactions of selexi
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 42(1)
The pharmacokinetic profile of ponesimod, a sphingosine-1-phosphate receptor 1 modulator, is characterized by a rapid absorption [time to maximum concentration (tAfter ensuring in a pilot phase the full pharmacokinetic profile, safety, and tolerabili
Autor:
Esen Yonca Bassoy, Margaux Boehler, Marta Calvo Tardón, Céline Yacoub Maroun, Pietro Taverna, Pierre-Yves Dietrich, Cristina Riccadonna, Romain Vuillefroy De Silly, Simone Jueliger, Denis Martinvalet, Leticia Barba, Paul R. Walker, Serena Pellegatta, Eliana Marinari
Publikováno v:
PLOS ONE, Vol. 11, No 8 (2016) P. e0162105
PLoS ONE, Vol 11, Iss 8, p e0162105 (2016)
PLoS ONE
PLoS ONE, Vol 11, Iss 8, p e0162105 (2016)
PLoS ONE
Malignant gliomas are aggressive brain tumours with very poor prognosis. The majority of glioma cells are differentiated (glioma-differentiated cells: GDCs), whereas the smaller population (glioma-initiating cells, GICs) is undifferentiated and resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7c3cdccaf74938b3b574dfc2bbf304
https://archive-ouverte.unige.ch/unige:89480
https://archive-ouverte.unige.ch/unige:89480